A provider's guide to helping patients afford Relexxii. Covers manufacturer savings cards, coupons, generic options, and how to build cost conversations into care.
If you prescribe Relexxii (methylphenidate hydrochloride extended-release) for ADHD, chances are you've had patients tell you they can't afford their medication — or worse, they've quietly stopped filling it without telling you. Medication cost is one of the most common reasons patients with ADHD become non-adherent, and with brand-name Relexxii costing $350-$505 per month at retail cash price, it's not hard to understand why.
The good news: there are multiple programs and strategies that can bring the cost of Relexxii down dramatically. This guide walks you through each option so you can point patients in the right direction — or have your staff do it as part of the prescribing workflow.
Understanding the cost landscape helps you anticipate which patients need help:
The biggest pain point is usually patients who either don't have insurance, have a high deductible they haven't met, or whose plan requires the brand and doesn't cover it well.
Vertical Pharmaceuticals offers a Relexxii Savings Card available at relexxii.com/savings. Key details:
How to integrate this: Keep the savings card URL in your EHR as a smart phrase or have printed cards at check-out. When writing a brand-name Relexxii prescription for a commercially insured patient, mention the savings card proactively.
For patients paying cash — whether uninsured or choosing to bypass insurance — several platforms offer significant discounts on generic methylphenidate ER:
GoodRx consistently offers some of the lowest cash prices for generic methylphenidate ER, often in the $32-$45/month range. Patients can look up prices, compare pharmacies, and show the coupon on their phone at the pharmacy counter.
Another reliable option with competitive pricing. Available at singlecare.com.
RxSaver, ScriptSave WellRx, Optum Perks, and BuzzRx all offer coupons for generic methylphenidate ER. Prices vary by pharmacy and location, so patients benefit from comparing across platforms.
Pro tip for your staff: If a patient reports a high copay, have them check GoodRx or SingleCare — in some cases, the cash price with a coupon is lower than the insurance copay, especially for generics. Patients can ask the pharmacist to run the coupon instead of insurance.
For many patients, the simplest cost-saving strategy is prescribing generic methylphenidate ER instead of brand Relexxii. Key considerations:
If you're prescribing brand Relexxii specifically because a patient had issues with a generic formulation (different release profile, side effects), document the medical necessity. This helps with insurance appeals and prior authorizations.
For patients who can't find their prescribed formulation, our guide on alternatives to Relexxii covers the full range of options, including other extended-release methylphenidate products like Aptensio XR and Jornay PM.
For patients without any insurance coverage:
No dedicated manufacturer patient assistance program (PAP) has been identified specifically for uninsured Relexxii patients, which makes the generic + coupon pathway the most practical route for this population.
Cost shouldn't be an afterthought — it should be part of the prescribing decision. Here are practical ways to integrate savings into your practice:
A simple question: "Are you having any trouble affording your medication?" Many patients won't volunteer this information. Normalizing the question makes it easier for them to ask for help.
Unless there's a specific clinical reason for brand Relexxii, prescribe generic methylphenidate ER. If you allow generic substitution, make sure the prescription doesn't say "brand necessary" or "DAW" unless intended.
Front desk and MA staff can be trained to:
Many EHR systems show real-time insurance formulary information and out-of-pocket cost estimates. Use these tools to identify high-cost prescriptions before the patient gets to the pharmacy and discovers the price.
Through a partnership with Relexxii's manufacturer, Medfinder offers complimentary medication locating services for Relexxii patients.
If a patient genuinely needs brand Relexxii (not generic), document why. Common clinical reasons include:
Good documentation supports prior authorization requests and insurance appeals.
If cost is a persistent barrier and generic methylphenidate ER isn't available or affordable, consider whether a different ADHD medication might be more accessible. Our provider shortage guide covers clinical considerations for switching during supply disruptions.
Cost savings don't matter if patients can't find the medication in stock. The stimulant shortage has made pharmacy stock unpredictable. Medfinder for Providers lets you and your staff check real-time pharmacy availability before sending a prescription, reducing the frustrating cycle of rejected fills and pharmacy transfers.
For a complete guide on navigating stock issues, see our provider resource: How to Help Your Patients Find Relexxii in Stock.
Helping patients afford Relexxii doesn't require a lot of extra time — it requires knowing what's available and building a few simple steps into your workflow. Between manufacturer savings cards, discount coupons, generic alternatives, and patient assistance programs, most patients can find a path to affordable ADHD treatment. The provider's role is to open that door.
The manufacturer of Relexxii has partnered with Medfinder to provide medication locating services free of charge. Visit medfinder.com to find Relexxii in stock near you at no cost.
For more clinical resources on managing Relexxii prescriptions during the current shortage, visit Medfinder for Providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
